ETF PROAI

IBBvsSPMD

iShares Biotechnology ETF against SPDR Portfolio S&P 400 Mid Cap ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IBB 136SPMD 112Oct 25Oct 26GROWTH OF $100
Head to head
IBBSPMD
Expense ratio0.45%0.030%
Assets$10.9B$18.1B
Net flow, 1 month+$272M+$190M
Net flow, 1 year+$1.8B+$2.1B
Return, YTD+21.6%+11.0%
Return, 1 year+36.0%+11.6%
Avg daily volume1.5M1.6M
Holdings221401
ListedFeb 5, 2001Nov 8, 2005
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.